COMPANY PRODUCT TYPE THERAPEUTIC AREA INDICATION PHASE PRODUCT
AbbVie Atrasentan Biodrugs/ Drugs Kidney and Genitourinary system Diabetic Nephropathy 3PhIII Atrasentan
Therapeutic area: Kidney and Genitourinary system
AbbVie ABT-SLV187 Biodrugs/ Drugs Central Nervous System Parkinson 4Reg. ABT-SLV187
Therapeutic area: Central Nervous System
AbbVie ABT-122 Biodrugs/ Drugs Autoimmune & Inflammation Psoriasic arthritis 2PhII ABT-122
Therapeutic area: Autoimmune & Inflammation
AbbVie Elagolix Biodrugs/ Drugs Women´s health Endometriosis 3PhIII Elagolix
Therapeutic area: Women´s health
AbbVie Rova-T Biodrugs/ Drugs Cancer Solid tumor 3PhIII Rova-T
Therapeutic area: Cancer
AbbVie ABT-981 Biodrugs/ Drugs Analgesia & Pain
Autoimmune & Inflammation
Knee Osteoarthritis 2PhII ABT-981
Therapeutic area: Analgesia & Pain / Autoimmune & Inflammation
AbbVie ABT-199/GDC0199 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Multiple mieloma 3PhIII ABT-199/GDC0199
Therapeutic area: Blood and Lymphatic systems / Cancer
AbbVie ABBV-221 Biodrugs/ Drugs Cancer EGFR (Epidermal growth factor receptor) 1PhI ABBV-221
Therapeutic area: Cancer
AbbVie SLV245-CREON Biodrugs/ Drugs Metabolic / Endocrinology Cystic fibrosis 3PhIII SLV245-CREON
Therapeutic area: Metabolic / Endocrinology
AbbVie ABT-494 Biodrugs/ Drugs Autoimmune & Inflammation Rheumatoid Arthritis, Crohn Disease 3PhIII ABT-494
Therapeutic area: Autoimmune & Inflammation
AbbVie HCV Interferon-Free Combination (genotype 1) Biodrugs/ Drugs Infections haepatitis C 3PhIII HCV Interferon-Free Combination (genotype 1)
Therapeutic area: Infections
AbbVie ABBV-399 Biodrugs/ Drugs Cancer Solid Tumor 2PhII ABBV-399
Therapeutic area: Cancer
AbbVie Veliparib Biodrugs/ Drugs Cancer Brain cancer, Breast, ovarian and colorectal Cancer, Non-small-cell lung carcinoma (NSCLC)and Small Cell Lung Cancer (SCLC ), Triple-negative breast cancer (TNBC), solid tumors 3PhIII Veliparib
Therapeutic area: Cancer
AbbVie ABBV-559 Biodrugs/ Drugs Autoimmune & Inflammation Rheumatoid arthritis 2PhII ABBV-559
Therapeutic area: Autoimmune & Inflammation
AbbVie ABBV-181 Biodrugs/ Drugs Cancer Solid tumor 1PhI ABBV-181
Therapeutic area: Cancer
AbbVie ABT-165 Biodrugs/ Drugs Cancer Solid Tumor 2PhII ABT-165
Therapeutic area: Cancer
AbbVie ABBV-621 Biodrugs/ Drugs Cancer Hematology 1PhI ABBV-621
Therapeutic area: Cancer
AbbVie Humira (adalimumab) Biodrugs/ Drugs Autoimmune & Inflammation Hidradenitis Suppurativa / Peripheral Spondyloarthritis / Uveitis / Ulcerative colitis / Chron Disease / Enthesitis paediatric / AR / Psoriasis 4Reg. Humira (adalimumab)
Therapeutic area: Autoimmune & Inflammation
AbbVie ABBV-8E12 Biodrugs/ Drugs Central Nervous System Alzheimer 2PhII ABBV-8E12
Therapeutic area: Central Nervous System
AbbVie ABT-414 Biodrugs/ Drugs Cancer Relapsed GBM / Incipient GBM 3PhIII ABT-414
Therapeutic area: Cancer
AbbVie ABBV-838 Biodrugs/ Drugs Cancer Multiple myeloma 1PhI ABBV-838
Therapeutic area: Cancer
AbbVie ABBV-927 Biodrugs/ Drugs Cancer Solid tumor 1PhI ABBV-927
Therapeutic area: Cancer
AbbVie ABV-085 Biodrugs/ Drugs Cancer Solid tumor 1PhI ABV-085
Therapeutic area: Cancer
AbbVie ABBV-927 Biodrugs/ Drugs Cancer Solid tumor 1PhI ABBV-927
Therapeutic area: Cancer
AbbVie ABBV-176 Biodrugs/ Drugs Cancer Solid tumor 1PhI ABBV-176
Therapeutic area: Cancer
AbbVie ABT-066 Biodrugs/ Drugs Autoimmune & Inflammation Psoriasis, Psoriatic arthritis, Crohn disease 3PhIII ABT-066
Therapeutic area: Autoimmune & Inflammation
Amgen Darbepoetin alfa Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Treatment of symptomatic anemia associated with chronic renal failure in adults / Treatment of symptomatic anemia in adult cancer patients with non-myeloid malignancies 3PhIII Darbepoetin alfa
Therapeutic area: Blood and Lymphatic systems / Cancer
Amgen Blinatumomab Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Acute lymphoblastic leukaemia 4Reg. Blinatumomab
Therapeutic area: Blood and Lymphatic systems / Cancer
Amgen Trebananib Biodrugs/ Drugs Cancer Ovarian Cancer 3PhIII Trebananib
Therapeutic area: Cancer
Amgen AMG 337 Biodrugs/ Drugs Cancer Gastric cancer 2PhII AMG 337
Therapeutic area: Cancer
Amgen AMG 334 Biodrugs/ Drugs Central Nervous System Migraine 2PhII AMG 334
Therapeutic area: Central Nervous System
Amgen Conatumumab Biodrugs/ Drugs Cancer Various cancer types 2PhII Conatumumab
Therapeutic area: Cancer
Amgen Etelcalcetide Biodrugs/ Drugs Metabolic / Endocrinology Secondary Hyperparathyroidism 4Reg. Etelcalcetide
Therapeutic area: Metabolic / Endocrinology
Amgen AMG 181 Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn´s disease 2PhII AMG 181
Therapeutic area: Autoimmune & Inflammation / Digestive System
Amgen Romosozumab Biodrugs/ Drugs Musculoskeletal Disorders
Women´s health
Postmenopausal osteoporosis 3PhIII Romosozumab
Therapeutic area: Musculoskeletal Disorders / Women´s health
Amgen Carfilzomib Biodrugs/ Drugs Cancer Mieloma 4Reg. Carfilzomib
Therapeutic area: Cancer
Amgen Denosumab Biodrugs/ Drugs Cancer Giant cell tumour of the bone 2PhII Denosumab
Therapeutic area: Cancer
Amgen Denosumab Biodrugs/ Drugs Musculoskeletal Disorders Osteoporosis in postmenopausal women / Treatment of bone loss associated with hormone ablation in men with prostate cancer 4Reg. Denosumab
Therapeutic area: Musculoskeletal Disorders
Amgen erenumab Biodrugs/ Drugs Central Nervous System Migraine 4Reg. erenumab
Therapeutic area: Central Nervous System
Amgen Evolocumab Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Hypercholesterolemia, mixed dyslipidemia and Homozygous familial hypercholesterolemia 4Reg. Evolocumab
Therapeutic area: Cardiovascular and circulatory systems / Metabolic / Endocrinology
Amgen Omecantiv mecarbil Biodrugs/ Drugs Cardiovascular and circulatory systems Heart failure 3PhIII Omecantiv mecarbil
Therapeutic area: Cardiovascular and circulatory systems
Amgen Brodalumab Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Psoriatic arthritis 4Reg. Brodalumab
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Amgen AMG 820 Biodrugs/ Drugs Cancer Solid tumors 2PhII AMG 820
Therapeutic area: Cancer
Amgen Talimogene laherparepvec Biodrugs/ Drugs Cancer Malignant melanoma 4Reg. Talimogene laherparepvec
Therapeutic area: Cancer
Amgen Romiplostim Biodrugs/ Drugs Blood and Lymphatic systems Adult chronic - immune (idiopatic)-thrombocytopenic-purpura (ITP) 4Reg. Romiplostim
Therapeutic area: Blood and Lymphatic systems
Amgen Brodalumab Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Psoriasis 4Reg. Brodalumab
Therapeutic area: Autoimmune & Inflammation / Dermatology
Amgen oprozomib Biodrugs/ Drugs Cancer Mieloma 2PhII oprozomib
Therapeutic area: Cancer
Amgen Cinacalcet Biodrugs/ Drugs Autoimmune & Inflammation
Kidney and Genitourinary system
Secondary hyperparathyroidism / Reducation of hypercalcaemia in patinents with parathyroid carcinoma or primary HPT 4Reg. Cinacalcet
Therapeutic area: Autoimmune & Inflammation / Kidney and Genitourinary system
Amgen Rilotumumab Biodrugs/ Drugs Cancer Various cancer types 3PhIII Rilotumumab
Therapeutic area: Cancer
Biogen Spain antiLingo Biodrugs/ Drugs Autoimmune & Inflammation
Central Nervous System
Multiple Sclerosis 2PhII antiLingo
Therapeutic area: Autoimmune & Inflammation / Central Nervous System
Biogen Spain Daclizumab Biodrugs/ Drugs Autoimmune & Inflammation
Central Nervous System
Multiple Sclerosis 3PhIII Daclizumab
Therapeutic area: Autoimmune & Inflammation / Central Nervous System
Biogen Spain BG-12 Biodrugs/ Drugs Autoimmune & Inflammation
Central Nervous System
Multiple Sclerosis 4Reg. BG-12
Therapeutic area: Autoimmune & Inflammation / Central Nervous System
Biogen Spain Natalizumab Biodrugs/ Drugs Autoimmune & Inflammation
Central Nervous System
Secondary Progressive Multiple Sclerosis 2PhII Natalizumab
Therapeutic area: Autoimmune & Inflammation / Central Nervous System
Biogen Spain antiLingo Biodrugs/ Drugs Ophthalmology and optometry Optic Neuritis 2PhII antiLingo
Therapeutic area: Ophthalmology and optometry
Biogen Spain anti-TWEAK Biodrugs/ Drugs Autoimmune & Inflammation
Kidney and Genitourinary system
Lupus Nephritis 2PhII anti-TWEAK
Therapeutic area: Autoimmune & Inflammation / Kidney and Genitourinary system
Biogen Spain IFN ß 1a pgilated Biodrugs/ Drugs Autoimmune & Inflammation
Central Nervous System
Multiple Sclerosis 4Reg. IFN ß 1a pgilated
Therapeutic area: Autoimmune & Inflammation / Central Nervous System
Celgene Tislelizumab Biodrugs/ Drugs Cancer solid tumors. non-small cell lung cancer. Hepatocellular carcinoma. Esophageal squamous cell carcinoma 3PhIII Tislelizumab
Therapeutic area: Cancer
Celgene Morgensen (GED-0301) Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Ulcerative colitis 2PhII Morgensen (GED-0301)
Therapeutic area: Autoimmune & Inflammation / Digestive System
Celgene PD-L1 Inhibitor:durvalumab Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Multiple Myeloma (MM) Chronic Lymphocytic Leukemia (CLL) No-Hodgkin Lymphoma (NHL) 1PhI PD-L1 Inhibitor:durvalumab
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene BET inhibitor: CC-90010 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
lymphoma. Non-hodgkin lymphoma (NHL) 1PhI BET inhibitor: CC-90010
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene Luspatercept (ACE-536) Biodrugs/ Drugs Cancer Myelofibrosis: MF Anemia 2PhII Luspatercept (ACE-536)
Therapeutic area: Cancer
Celgene CC-90009 Biodrugs/ Drugs Blood and Lymphatic systems Acute Myeloid Leukemia (AML) 1PhI CC-90009
Therapeutic area: Blood and Lymphatic systems
Celgene REVLIMID® (lenalidomide) Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse large B-cell lymphoma (ABC subtype): First line Indolent lymphoma: relapsed/refractory Follicular lymphoma: first line 3PhIII REVLIMID® (lenalidomide)
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene AG-221 Biodrugs/ Drugs Blood and Lymphatic systems Acute Myeloid Leukemia (AML) 3PhIII AG-221
Therapeutic area: Blood and Lymphatic systems
Celgene PDA-002 Biodrugs/ Drugs Others Diabetic foot ulcers Diabetic peripheral neuropathy 2PhII PDA-002
Therapeutic area: Others
Celgene BET inhibitor: CC-90010 Biodrugs/ Drugs Cancer Solid tumors 1PhI BET inhibitor: CC-90010
Therapeutic area: Cancer
Celgene Abraxane (paclitaxel proteinbound particle for injectable susoension) ( Albumin-bound) /(paclitaxel formulated as albuminbound nanoparticles) Biodrugs/ Drugs Cancer Solid tumors , breast metastatic. Nonsmall cell lung advanded (First line) Pancratic metastatic ( First line) gastric metastatic ( Japan) 4Reg. Abraxane (paclitaxel proteinbound particle for injectable susoension) ( Albumin-bound) /(paclitaxel formulated as albuminbound nanoparticles)
Therapeutic area: Cancer
Celgene CC-220 Biodrugs/ Drugs Autoimmune & Inflammation Systemic lupus erythematosus 2PhII CC-220
Therapeutic area: Autoimmune & Inflammation
Celgene AG-120 Biodrugs/ Drugs Blood and Lymphatic systems Acute Myeloid Leukemia (AML) 1PhI AG-120
Therapeutic area: Blood and Lymphatic systems
Celgene CC-486 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Myelodysplastic Syndromes (MDS): lower-risk Post-induction AML maintenance 3PhIII CC-486
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene PNK-007 Biodrugs/ Drugs Blood and Lymphatic systems Acute Myeloid Leukemia (AML) Multiple Myeloma (MM) 1PhI PNK-007
Therapeutic area: Blood and Lymphatic systems
Celgene Avadomide (CC-122) Biodrugs/ Drugs Blood and Lymphatic systems Lymphoma. Diffuse large B-cell lymphoma 1PhI Avadomide (CC-122)
Therapeutic area: Blood and Lymphatic systems
Celgene ISTODAX ( romidepsin) for injection Biodrugs/ Drugs Blood and Lymphatic systems Lymphoma. Cutaneous T-cell Lymphoma (US). 4Reg. ISTODAX ( romidepsin) for injection
Therapeutic area: Blood and Lymphatic systems
Celgene CC-90006 Biodrugs/ Drugs Autoimmune & Inflammation Autoinmune disorders:psoriasis 1PhI CC-90006
Therapeutic area: Autoimmune & Inflammation
Celgene CAR-T (JCAR15) Biodrugs/ Drugs Blood and Lymphatic systems ALL( Accute Lymphoblastic Leukemia) 2PhII CAR-T (JCAR15)
Therapeutic area: Blood and Lymphatic systems
Celgene CC 486 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Breast: Metastatic Non-small cell lung: Advanced Myelodysplastic Syndromes (MDS): post hypomethylating agent (HMA) failure 2PhII CC 486
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene Mongersen (GED 0301) Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn's disease 3PhIII Mongersen (GED 0301)
Therapeutic area: Autoimmune & Inflammation / Digestive System
Celgene CC-122 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoma: Diffuse large B-Cell & Indolent lymphoma: relapsed/refractory Hepatocellular carcinoma Multiple Myeloma Chronic Lymphocytic Leukemia (CLL) 1PhI CC-122
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene AG-881 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Acute Myeloid Leukemia (AML) Glioma 1PhI AG-881
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene Pomalyst ( imnovid ( pomalidomide) Biodrugs/ Drugs Blood and Lymphatic systems Multiple Myeloma (MM) Relapsed/ refractory 4Reg. Pomalyst ( imnovid ( pomalidomide)
Therapeutic area: Blood and Lymphatic systems
Celgene REVLIMID ( lenalidomida) Biodrugs/ Drugs Blood and Lymphatic systems Multiple Myelome (MM): Relapsed/refractory Newly diagnosed Maintenance Myelodyplastic syndromes (MDS) deletion 5q. lymphoma: mantle cell lymphoma , relapsed/ refratory. 4Reg. REVLIMID ( lenalidomida)
Therapeutic area: Blood and Lymphatic systems
Celgene Luspatercept (ACE-536) Biodrugs/ Drugs Blood and Lymphatic systems
Others
Myelodisplastic Syndromes (MDS) Beta-thalassemia 3PhIII Luspatercept (ACE-536)
Therapeutic area: Blood and Lymphatic systems / Others
Celgene OTEZLA® (Apremilast) Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Ankylosing spondylitis Behcets disease 4Reg. OTEZLA® (Apremilast)
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Celgene RPC4046 Biodrugs/ Drugs Autoimmune & Inflammation Eosinophilic esophagitis 2PhII RPC4046
Therapeutic area: Autoimmune & Inflammation
Celgene CD19 CAR-T (JCAR017) Biodrugs/ Drugs Blood and Lymphatic systems Aggressive large B-cell lymphoma: Relapsed/refractory 1PhI CD19 CAR-T (JCAR017)
Therapeutic area: Blood and Lymphatic systems
Celgene Thalomid / thalidomide celgene (Thalidomide) Biodrugs/ Drugs Blood and Lymphatic systems Multiple Myeloma (MM) Relapsed/ refractory 4Reg. Thalomid / thalidomide celgene (Thalidomide)
Therapeutic area: Blood and Lymphatic systems
Celgene PPM Pleiotropic Pathway Modifier: CC-122 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Hepatocellular carcinoma 2PhII PPM Pleiotropic Pathway Modifier: CC-122
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene ABRAXANE® Biodrugs/ Drugs Cancer Pancreatic:Adjuvant 3PhIII ABRAXANE®
Therapeutic area: Cancer
Celgene REVLIMID ( lenalidomide) Biodrugs/ Drugs Blood and Lymphatic systems lymphoma: Adult T-cell leukemia- lymphoma (Japan) 3PhIII REVLIMID ( lenalidomide)
Therapeutic area: Blood and Lymphatic systems
Celgene BCMA CAR-T (bb2121) Biodrugs/ Drugs Blood and Lymphatic systems Multiple Myeloma (MM) 1PhI BCMA CAR-T (bb2121)
Therapeutic area: Blood and Lymphatic systems
Celgene BCMA CAR T (JCARH125) Biodrugs/ Drugs Blood and Lymphatic systems Multiple Myeloma (MM) 1PhI BCMA CAR T (JCARH125)
Therapeutic area: Blood and Lymphatic systems
Celgene Ozanimod Biodrugs/ Drugs Autoimmune & Inflammation Ulcerative colitis Relapsing multiple sclerosis 3PhIII Ozanimod
Therapeutic area: Autoimmune & Inflammation
Celgene VIDAZA® (azacitidine for injection) Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Acute myeloid laeukemia (AML) (>30% blasts) 4Reg. VIDAZA® (azacitidine for injection)
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene OTEZLA (apremilast) Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Psoriatic arthritis (PsA) Psoriasis 4Reg. OTEZLA (apremilast)
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Celgene Citarinostat (ACY-241) Biodrugs/ Drugs Blood and Lymphatic systems Multiple Myeloma (MM) relapsed/refractory 1PhI Citarinostat (ACY-241)
Therapeutic area: Blood and Lymphatic systems
Celgene CC-92480 Biodrugs/ Drugs Blood and Lymphatic systems Multiple Myeloma (MM) Relapsed/ refractory 1PhI CC-92480
Therapeutic area: Blood and Lymphatic systems
Celgene Ozanimod Biodrugs/ Drugs Autoimmune & Inflammation Crohn`s disease 3PhIII Ozanimod
Therapeutic area: Autoimmune & Inflammation
Celgene IDHIFA (enasidenib) Biodrugs/ Drugs Blood and Lymphatic systems Myelodyplastic Syndromes (MDS) RElapsed/refractory IDH2 mutation (US) 4Reg. IDHIFA (enasidenib)
Therapeutic area: Blood and Lymphatic systems
Celgene LSD1 Inhibitor: CC-90011 Biodrugs/ Drugs Cancer Solid tumors 1PhI LSD1 Inhibitor: CC-90011
Therapeutic area: Cancer
Celgene CC-93269 Biodrugs/ Drugs Blood and Lymphatic systems Multiple Myeloma (MM) Relapsed/ refractory 1PhI CC-93269
Therapeutic area: Blood and Lymphatic systems
Celgene ISTODAX® (romidepsin) Biodrugs/ Drugs Blood and Lymphatic systems Peripheral T-cell lymphoma:First-line 3PhIII ISTODAX® (romidepsin)
Therapeutic area: Blood and Lymphatic systems
Celgene SOTATERCEPT (ACE-011) Biodrugs/ Drugs Autoimmune & Inflammation Chronic kidney disease 2PhII SOTATERCEPT (ACE-011)
Therapeutic area: Autoimmune & Inflammation
Celgene IDHIFA (enasidenib) Biodrugs/ Drugs Blood and Lymphatic systems myelody syndromes (MDS(Newly diagnosed AML with an IDH2 mutation 1PhI IDHIFA (enasidenib)
Therapeutic area: Blood and Lymphatic systems
Celgene OTEZLA® (apremilast) Biodrugs/ Drugs Autoimmune & Inflammation Ulcerative colitis 2PhII OTEZLA® (apremilast)
Therapeutic area: Autoimmune & Inflammation
Celgene PD-L1 Inhibitor: durvalumab Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Myelodysplastic Syndromes (MDS) Acute Myeloid Leukemia (AML) 2PhII PD-L1 Inhibitor: durvalumab
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene Fedratinib Biodrugs/ Drugs Autoimmune & Inflammation Myelofibrosis: MF anemia 3PhIII Fedratinib
Therapeutic area: Autoimmune & Inflammation
Celgene CC 486 Biodrugs/ Drugs Blood and Lymphatic systems Lymphoma 1PhI CC 486
Therapeutic area: Blood and Lymphatic systems
Celgene CC-220 Biodrugs/ Drugs Blood and Lymphatic systems Multiple Myeloma (MM) relapsed/refractory 1PhI CC-220
Therapeutic area: Blood and Lymphatic systems
Celgene CC-486 Biodrugs/ Drugs Blood and Lymphatic systems Lymphoma 1PhI CC-486
Therapeutic area: Blood and Lymphatic systems
Celgene Anti-CD47 Antibody: CC-90002 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Myelodysplastic Syndromes (MDS) Acute Myeloid Leukemia (AML) Solid Tumors lymphoma: non-hogdkin lymphoma (NHL) 1PhI Anti-CD47 Antibody: CC-90002
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene Marizomib Biodrugs/ Drugs Cancer solid tumors. Glioblastoma 2PhII Marizomib
Therapeutic area: Cancer
Celgene ISTODAX® (romidepsin) Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Peripheral T-cell lymphoma: relapsed/refractory (Japan) 2PhII ISTODAX® (romidepsin)
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene CC-90001 Biodrugs/ Drugs Autoimmune & Inflammation Fibrosis 2PhII CC-90001
Therapeutic area: Autoimmune & Inflammation
Celgene CC-486 Biodrugs/ Drugs Blood and Lymphatic systems Breast. metastatic nonsmall cell lung: advanced myelodysplastic syndromes ( MDS) : post hypomethylating agent (HMA) failure. 2PhII CC-486
Therapeutic area: Blood and Lymphatic systems
Genzyme Aubagio® (teriflunomida) Biodrugs/ Drugs Autoimmune & Inflammation
Central Nervous System
Multiple Sclerosis 4Reg. Aubagio® (teriflunomida)
Therapeutic area: Autoimmune & Inflammation / Central Nervous System
Genzyme Alemtuzumab Biodrugs/ Drugs Autoimmune & Inflammation
Central Nervous System
Multiple Sclerosis 4Reg. Alemtuzumab
Therapeutic area: Autoimmune & Inflammation / Central Nervous System
Genzyme Eliglustat Biodrugs/ Drugs Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
Lysosomal Diseases; Gaucher Disease 4Reg. Eliglustat
Therapeutic area: Genetic Diseases and Dysmorphic syndromes / Metabolic / Endocrinology
Gilead Sciences Axicabtagene colileucel Biodrugs/ Drugs Blood and Lymphatic systems Indolent NHL 2PhII Axicabtagene colileucel
Therapeutic area: Blood and Lymphatic systems
Gilead Sciences Simtuzumab Biodrugs/ Drugs Digestive System Liver fibrosis, primary sclerosing cholangitis, nonalcoholic steatohaepatitis 2PhII Simtuzumab
Therapeutic area: Digestive System
Gilead Sciences Alafenamide STR Biodrugs/ Drugs Infections HIV/AIDS 3PhIII Alafenamide STR
Therapeutic area: Infections
Gilead Sciences GS-9876 (Syk inhibitor) Biodrugs/ Drugs Autoimmune & Inflammation Lupus 2PhII GS-9876 (Syk inhibitor)
Therapeutic area: Autoimmune & Inflammation
Gilead Sciences KTE-C19 Biodrugs/ Drugs Blood and Lymphatic systems MCL 2PhII KTE-C19
Therapeutic area: Blood and Lymphatic systems
Gilead Sciences Simtuzumab Biodrugs/ Drugs Respiratory and Pulmonary system Idiopathic pulmonary fibrosis 2PhII Simtuzumab
Therapeutic area: Respiratory and Pulmonary system
Gilead Sciences Emtricitabine/Tenofovir alafenamide FDC Biodrugs/ Drugs Infections HIV/AIDS 3PhIII Emtricitabine/Tenofovir alafenamide FDC
Therapeutic area: Infections
Gilead Sciences Selonsertib ( ASK-1 Inhibitor) Biodrugs/ Drugs Metabolic / Endocrinology NASH 3PhIII Selonsertib ( ASK-1 Inhibitor)
Therapeutic area: Metabolic / Endocrinology
Gilead Sciences GS-4875 (TPL2 inhibitor) Biodrugs/ Drugs Autoimmune & Inflammation Inflammatory Bowel 1PhI GS-4875 (TPL2 inhibitor)
Therapeutic area: Autoimmune & Inflammation
Gilead Sciences KTE-C19 Biodrugs/ Drugs Blood and Lymphatic systems Adult ALL 1PhI KTE-C19
Therapeutic area: Blood and Lymphatic systems
Gilead Sciences Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide STR Biodrugs/ Drugs Infections HIV/AIDS 3PhIII Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide STR
Therapeutic area: Infections
Gilead Sciences Selonsertib ( ASK-1 Inhibitor) Biodrugs/ Drugs Metabolic / Endocrinology Alcoholic Hepatitis 2PhII Selonsertib ( ASK-1 Inhibitor)
Therapeutic area: Metabolic / Endocrinology
Gilead Sciences Remdesivir ( Gs-5734, Nuc. Inhibitor) Biodrugs/ Drugs Infections Ebola Virus infection 2PhII Remdesivir ( Gs-5734, Nuc. Inhibitor)
Therapeutic area: Infections
Gilead Sciences KTE-C19 Biodrugs/ Drugs Blood and Lymphatic systems Pedriatic ALL 1PhI KTE-C19
Therapeutic area: Blood and Lymphatic systems
Gilead Sciences GS-9674 (FXR Agonist) Biodrugs/ Drugs Metabolic / Endocrinology NASH 2PhII GS-9674 (FXR Agonist)
Therapeutic area: Metabolic / Endocrinology
Gilead Sciences Tirabrutinib (BTK inhibitor) Biodrugs/ Drugs Blood and Lymphatic systems B-cell malignancies 2PhII Tirabrutinib (BTK inhibitor)
Therapeutic area: Blood and Lymphatic systems
Gilead Sciences GS-5806 (fusion inhibitor) Biodrugs/ Drugs Infections
Respiratory and Pulmonary system
Respiratory syncytial virus 2PhII GS-5806 (fusion inhibitor)
Therapeutic area: Infections / Respiratory and Pulmonary system
Gilead Sciences GS-9674 (FXR Agonist) Biodrugs/ Drugs Metabolic / Endocrinology Primary Bilinary Cirrhosis 2PhII GS-9674 (FXR Agonist)
Therapeutic area: Metabolic / Endocrinology
Gilead Sciences KITE-585 ( anti-BCMA) Biodrugs/ Drugs Blood and Lymphatic systems MM 1PhI KITE-585 ( anti-BCMA)
Therapeutic area: Blood and Lymphatic systems
Gilead Sciences GS-6615 (late sodium current inhibitor) Biodrugs/ Drugs Cardiovascular and circulatory systems Ventricular tachycardia / Ventricular fibrillation 2PhII GS-6615 (late sodium current inhibitor)
Therapeutic area: Cardiovascular and circulatory systems
Gilead Sciences GS-9674 (FXR Agonist) Biodrugs/ Drugs Metabolic / Endocrinology Primary Sclerosing Cholangit 2PhII GS-9674 (FXR Agonist)
Therapeutic area: Metabolic / Endocrinology
Gilead Sciences KITE-718 ( MAGE A3/A6) Biodrugs/ Drugs Cancer Solid tumor. 1PhI KITE-718 ( MAGE A3/A6)
Therapeutic area: Cancer
Gilead Sciences GS-4997 (ASK-1 inhibitor) Biodrugs/ Drugs Cardiovascular and circulatory systems Pulmonary arterial hypertension 2PhII GS-4997 (ASK-1 inhibitor)
Therapeutic area: Cardiovascular and circulatory systems
Gilead Sciences GS-0976 ( ACC Inhibitor) Biodrugs/ Drugs Metabolic / Endocrinology NASH 2PhII GS-0976 ( ACC Inhibitor)
Therapeutic area: Metabolic / Endocrinology
Gilead Sciences Andecaliximab (MMP9 mAb inhibitor) Biodrugs/ Drugs Cancer Gastric cancer 3PhIII Andecaliximab (MMP9 mAb inhibitor)
Therapeutic area: Cancer
Gilead Sciences GS-5745 (MMP9 mAb inhibitor) Biodrugs/ Drugs Autoimmune & Inflammation Ulcerative colitis 2PhII GS-5745 (MMP9 mAb inhibitor)
Therapeutic area: Autoimmune & Inflammation
Gilead Sciences ERK Inhibitor Biodrugs/ Drugs Cancer Cancer 1PhI ERK Inhibitor
Therapeutic area: Cancer
Gilead Sciences Vestalimod ( GS-9620, TRL-7 agonist) Biodrugs/ Drugs Infections HIV/AIDS 1PhI Vestalimod ( GS-9620, TRL-7 agonist)
Therapeutic area: Infections
Gilead Sciences Filgotinib (JAK1 inhibitor) Biodrugs/ Drugs Autoimmune & Inflammation Rheumatoid Arthritis 3PhIII Filgotinib (JAK1 inhibitor)
Therapeutic area: Autoimmune & Inflammation
Gilead Sciences Andecaliximab (MMP9 mAb inhibitor) Biodrugs/ Drugs Cancer Solid tumors 1PhI Andecaliximab (MMP9 mAb inhibitor)
Therapeutic area: Cancer
Gilead Sciences GS-5745 (MMP9 mAb inhibitor) Biodrugs/ Drugs Cancer Solid tumors 2PhII GS-5745 (MMP9 mAb inhibitor)
Therapeutic area: Cancer
Gilead Sciences GS-62'7 (capsid inhibitor) Biodrugs/ Drugs Infections HIV/AIDS 1PhI GS-62'7 (capsid inhibitor)
Therapeutic area: Infections
Gilead Sciences Filgotinib (JAK1 inhibitor) Biodrugs/ Drugs Autoimmune & Inflammation Crohn's Disease and Ulcerative colitis 2PhII Filgotinib (JAK1 inhibitor)
Therapeutic area: Autoimmune & Inflammation
Gilead Sciences Entosplenitib (Syk inhibitor) Biodrugs/ Drugs Blood and Lymphatic systems Hematological malignances 2PhII Entosplenitib (Syk inhibitor)
Therapeutic area: Blood and Lymphatic systems
Gilead Sciences Momelotinib Biodrugs/ Drugs Cancer Pancreatic cancer 2PhII Momelotinib
Therapeutic area: Cancer
Gilead Sciences GS-9131 (NRTI) Biodrugs/ Drugs Infections HIV/AIDS 3PhIII GS-9131 (NRTI)
Therapeutic area: Infections
Gilead Sciences GS-9722 (bNab) Biodrugs/ Drugs Infections HIV/AIDS 1PhI GS-9722 (bNab)
Therapeutic area: Infections
Gilead Sciences Presatovir ( Fusion inhibitor) Biodrugs/ Drugs Respiratory and Pulmonary system Respiratory Syncytial Virus 2PhII Presatovir ( Fusion inhibitor)
Therapeutic area: Respiratory and Pulmonary system
Gilead Sciences GS-4997 (ASK-1 inhibitor) Biodrugs/ Drugs Digestive System Nonalcoholic steatohaepatitis 2PhII GS-4997 (ASK-1 inhibitor)
Therapeutic area: Digestive System
Gilead Sciences Emtricitabine/Tenofovir alafenamide FDC/ Bictegravir/ Emtricitabine/Tenofovir Biodrugs/ Drugs Infections HIV/AIDS - PreExposure Profilaxis 3PhIII Emtricitabine/Tenofovir alafenamide FDC/ Bictegravir/ Emtricitabine/Tenofovir
Therapeutic area: Infections
Gilead Sciences Axicabtagene ciloleucel Biodrugs/ Drugs Blood and Lymphatic systems DLBCL ,PMBCL & TFL 3PhIII Axicabtagene ciloleucel
Therapeutic area: Blood and Lymphatic systems
Gilead Sciences GS-9876 ( Syk Inhibitor) Biodrugs/ Drugs Autoimmune & Inflammation Sjogren's Syndrome 2PhII GS-9876 ( Syk Inhibitor)
Therapeutic area: Autoimmune & Inflammation
Gilead Sciences GS-9688 (TLR-8 Agonist) Biodrugs/ Drugs Infections HBV 1PhI GS-9688 (TLR-8 Agonist)
Therapeutic area: Infections
LILLY Prexasertib Biodrugs/ Drugs Cancer cancer 2PhII Prexasertib
Therapeutic area: Cancer
LILLY Empagliflozin Biodrugs/ Drugs Metabolic / Endocrinology Type 1 Diabetes 3PhIII Empagliflozin
Therapeutic area: Metabolic / Endocrinology
LILLY IL-23 antibody Biodrugs/ Drugs Autoimmune & Inflammation ulcerative colitis 2PhII IL-23 antibody
Therapeutic area: Autoimmune & Inflammation
LILLY Baricitinib Biodrugs/ Drugs Autoimmune & Inflammation atopic dermatitis 3PhIII Baricitinib
Therapeutic area: Autoimmune & Inflammation
LILLY N3pG-AB Monoclonal Antibody Biodrugs/ Drugs Central Nervous System Alzheimer's disease 2PhII N3pG-AB Monoclonal Antibody
Therapeutic area: Central Nervous System
LILLY Abemaciclib Biodrugs/ Drugs Cancer adjuvant breast cancer 3PhIII Abemaciclib
Therapeutic area: Cancer
LILLY Nasal glucagon Biodrugs/ Drugs Metabolic / Endocrinology Severe Hypoglycemia in people with diabetes treated with insuline 3PhIII Nasal glucagon
Therapeutic area: Metabolic / Endocrinology
LILLY PCSK9 Monoclonal Antibody Biodrugs/ Drugs Cardiovascular and circulatory systems cardiovascular disease 2PhII PCSK9 Monoclonal Antibody
Therapeutic area: Cardiovascular and circulatory systems
LILLY Ixekizumab Biodrugs/ Drugs Autoimmune & Inflammation radiographic axial spondyloarthritis 3PhIII Ixekizumab
Therapeutic area: Autoimmune & Inflammation
LILLY Tau Monoclonal Antibody Biodrugs/ Drugs Central Nervous System Alzheimer's disease 1PhI Tau Monoclonal Antibody
Therapeutic area: Central Nervous System
LILLY Il-23/CGRP Dispecific Antibody Biodrugs/ Drugs Autoimmune & Inflammation Autoimmune diseases 1PhI Il-23/CGRP Dispecific Antibody
Therapeutic area: Autoimmune & Inflammation
LILLY Automated Insulin Delivery system (AID) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes 1PhI Automated Insulin Delivery system (AID)
Therapeutic area: Metabolic / Endocrinology
LILLY Ultra-rapid Insulin Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 and 2 3PhIII Ultra-rapid Insulin
Therapeutic area: Metabolic / Endocrinology
LILLY Selective BACE 1 inhibitor Biodrugs/ Drugs Central Nervous System Alzheimer's disease 1PhI Selective BACE 1 inhibitor
Therapeutic area: Central Nervous System
LILLY Angiopoietin 2 Mab cancer Biodrugs/ Drugs Cancer cancer 1PhI Angiopoietin 2 Mab cancer
Therapeutic area: Cancer
LILLY IL-2 PEG Biodrugs/ Drugs Autoimmune & Inflammation autoimmune diseases 1PhI IL-2 PEG
Therapeutic area: Autoimmune & Inflammation
LILLY Basal insulin-Fc Biodrugs/ Drugs Metabolic / Endocrinology Diabetes 1PhI Basal insulin-Fc
Therapeutic area: Metabolic / Endocrinology
LILLY CXCR4 Peptide Antagonist Biodrugs/ Drugs Cancer cancer 2PhII CXCR4 Peptide Antagonist
Therapeutic area: Cancer
LILLY D1 Potentiator Biodrugs/ Drugs Central Nervous System Demetia associated with parkinson's disease 2PhII D1 Potentiator
Therapeutic area: Central Nervous System
LILLY CSF-1R Monoclonal Antibody Biodrugs/ Drugs Cancer cancer 1PhI CSF-1R Monoclonal Antibody
Therapeutic area: Cancer
LILLY IDO1 Inhibitor Biodrugs/ Drugs Cancer cancer 1PhI IDO1 Inhibitor
Therapeutic area: Cancer
LILLY IL-33 Antibody Biodrugs/ Drugs Autoimmune & Inflammation autoimmune diseases 1PhI IL-33 Antibody
Therapeutic area: Autoimmune & Inflammation
LILLY Dual Amylin Calcitonin Receptor Agonist Biodrugs/ Drugs Metabolic / Endocrinology Diabetes 1PhI Dual Amylin Calcitonin Receptor Agonist
Therapeutic area: Metabolic / Endocrinology
LILLY Emibetuzumab Biodrugs/ Drugs Cancer NSCLC 2PhII Emibetuzumab
Therapeutic area: Cancer
LILLY N3pG-AB Monocloal antibody + BACE inhibitor Biodrugs/ Drugs Central Nervous System Alzheimer's disease 2PhII N3pG-AB Monocloal antibody + BACE inhibitor
Therapeutic area: Central Nervous System
LILLY FGFR3-ADC Biodrugs/ Drugs Cancer cancer 1PhI FGFR3-ADC
Therapeutic area: Cancer
LILLY PD-L1 monoclonal Antibody + LY Combo Biodrugs/ Drugs Cancer cancer 1PhI PD-L1 monoclonal Antibody + LY Combo
Therapeutic area: Cancer
LILLY PDE 4 inhibitor Biodrugs/ Drugs Autoimmune & Inflammation autoimmune diseases 1PhI PDE 4 inhibitor
Therapeutic area: Autoimmune & Inflammation
LILLY GPR142 Agonist Biodrugs/ Drugs Metabolic / Endocrinology Diabetes 1PhI GPR142 Agonist
Therapeutic area: Metabolic / Endocrinology
LILLY Ixekizumab Biodrugs/ Drugs Autoimmune & Inflammation non-radriographic axial spondyloarthritis 3PhIII Ixekizumab
Therapeutic area: Autoimmune & Inflammation
LILLY Flortaucipir F18 Biodrugs/ Drugs Central Nervous System tau pathology 3PhIII Flortaucipir F18
Therapeutic area: Central Nervous System
LILLY BAFF/ IL-17 bispecific antibody Biodrugs/ Drugs Autoimmune & Inflammation autoimmune diseases 1PhI BAFF/ IL-17 bispecific antibody
Therapeutic area: Autoimmune & Inflammation
LILLY Oxyntomodulin Biodrugs/ Drugs Metabolic / Endocrinology diabetes 1PhI Oxyntomodulin
Therapeutic area: Metabolic / Endocrinology
LILLY TGF-beta Receptor I Kinase Inhibitor Biodrugs/ Drugs Cancer Cancer 1PhI TGF-beta Receptor I Kinase Inhibitor
Therapeutic area: Cancer
LILLY Galcanezumab Biodrugs/ Drugs Analgesia & Pain cluster headache 3PhIII Galcanezumab
Therapeutic area: Analgesia & Pain
LILLY Baricitinib Biodrugs/ Drugs Autoimmune & Inflammation systemic lupus erythematosus 2PhII Baricitinib
Therapeutic area: Autoimmune & Inflammation
LILLY Hypoglycemia Biodrugs/ Drugs Metabolic / Endocrinology Diabetes 1PhI Hypoglycemia
Therapeutic area: Metabolic / Endocrinology
LILLY Lanabecestat Biodrugs/ Drugs Central Nervous System Alzheimer's disease 3PhIII Lanabecestat
Therapeutic area: Central Nervous System
LILLY CXCR1/2 Ligands Antibody Biodrugs/ Drugs Autoimmune & Inflammation autoimmune diseases 1PhI CXCR1/2 Ligands Antibody
Therapeutic area: Autoimmune & Inflammation
LILLY PD-L1 Antibody Biodrugs/ Drugs Cancer cancer 1PhI PD-L1 Antibody
Therapeutic area: Cancer
LILLY Galcanezumab Biodrugs/ Drugs Analgesia & Pain chronic and episodic migraine 4Reg. Galcanezumab
Therapeutic area: Analgesia & Pain
LILLY TIM-3 Monoclonal Antibody Biodrugs/ Drugs Cancer cancer 1PhI TIM-3 Monoclonal Antibody
Therapeutic area: Cancer
LILLY BTK inhibitor Biodrugs/ Drugs Autoimmune & Inflammation immune disorders 2PhII BTK inhibitor
Therapeutic area: Autoimmune & Inflammation
LILLY Dual Amylin Calcitonin Receptor Agonist Biodrugs/ Drugs Metabolic / Endocrinology Diabetes 1PhI Dual Amylin Calcitonin Receptor Agonist
Therapeutic area: Metabolic / Endocrinology
LILLY Lasmiditan Biodrugs/ Drugs Central Nervous System Migraine 3PhIII Lasmiditan
Therapeutic area: Central Nervous System
LILLY IL-21 Monoclonal Antibody Biodrugs/ Drugs Autoimmune & Inflammation autoimmune diseases 1PhI IL-21 Monoclonal Antibody
Therapeutic area: Autoimmune & Inflammation
LILLY AB42 Antibody Biodrugs/ Drugs Central Nervous System Alzheimer's disease 1PhI AB42 Antibody
Therapeutic area: Central Nervous System
LILLY Abemaciclib Biodrugs/ Drugs Cancer Hormone receptor positive and HER2 positivie metastasic breast cancer 2PhII Abemaciclib
Therapeutic area: Cancer
LILLY Ramucirumab Biodrugs/ Drugs Cancer bladder cancer 3PhIII Ramucirumab
Therapeutic area: Cancer
LILLY Mirikizumab Biodrugs/ Drugs Autoimmune & Inflammation Crohn's disease 2PhII Mirikizumab
Therapeutic area: Autoimmune & Inflammation
LILLY Tanezumab Biodrugs/ Drugs Cancer cancer pain 3PhIII Tanezumab
Therapeutic area: Cancer
LILLY GIP/GLP-1 Co-agonist peptide Biodrugs/ Drugs Metabolic / Endocrinology diabetes 2PhII GIP/GLP-1 Co-agonist peptide
Therapeutic area: Metabolic / Endocrinology
LILLY Merestinib Biodrugs/ Drugs Cancer cancer 2PhII Merestinib
Therapeutic area: Cancer
LILLY Dulaglutide 3.0 / 4.5 mg Biodrugs/ Drugs Metabolic / Endocrinology type 2 diabetes 3PhIII Dulaglutide 3.0 / 4.5 mg
Therapeutic area: Metabolic / Endocrinology
LILLY Ramucirumab Biodrugs/ Drugs Cancer hepatocellular carcinoma 3PhIII Ramucirumab
Therapeutic area: Cancer
LILLY Mirikizumab Biodrugs/ Drugs Autoimmune & Inflammation Psioriasis 2PhII Mirikizumab
Therapeutic area: Autoimmune & Inflammation
LILLY no name Biodrugs/ Drugs Metabolic / Endocrinology hypoglycemia 1PhI no name
Therapeutic area: Metabolic / Endocrinology
LILLY Tanezumab Biodrugs/ Drugs Analgesia & Pain Chronic lower back pain 3PhIII Tanezumab
Therapeutic area: Analgesia & Pain
LILLY pl3 Kinase/mTOR Dual inhibitor Biodrugs/ Drugs Cancer cancer 2PhII pl3 Kinase/mTOR Dual inhibitor
Therapeutic area: Cancer
LILLY Empagliflozin Biodrugs/ Drugs Metabolic / Endocrinology Chronic heart failure 3PhIII Empagliflozin
Therapeutic area: Metabolic / Endocrinology
LILLY Ramucirumab Biodrugs/ Drugs Cancer NSCLC 3PhIII Ramucirumab
Therapeutic area: Cancer
LILLY Mirikizumab Biodrugs/ Drugs Autoimmune & Inflammation ulcerative colitis 2PhII Mirikizumab
Therapeutic area: Autoimmune & Inflammation
LILLY insulin-Fc/Dula Biodrugs/ Drugs Metabolic / Endocrinology Diabetes 1PhI insulin-Fc/Dula
Therapeutic area: Metabolic / Endocrinology
LILLY Tanezumab Biodrugs/ Drugs Analgesia & Pain osteoarthritis pain 3PhIII Tanezumab
Therapeutic area: Analgesia & Pain
Merck M9241 (NHS-IL12) Biodrugs/ Drugs Cancer Solid tumors 2PhII M9241 (NHS-IL12)
Therapeutic area: Cancer
Merck Atacicept Biodrugs/ Drugs Autoimmune & Inflammation Systemic lupus erythematosus and IgA nephropathy 2PhII Atacicept
Therapeutic area: Autoimmune & Inflammation
Merck Tepotinib Biodrugs/ Drugs Cancer non-Smaill Lung cancer and hepatocellular 2PhII Tepotinib
Therapeutic area: Cancer
Merck Evobrutinib BTK inhibitor Biodrugs/ Drugs Central Nervous System Multiple Sclerosis 2PhII Evobrutinib BTK inhibitor
Therapeutic area: Central Nervous System
Merck M7824 / TGF beta trap Biodrugs/ Drugs Autoimmune & Inflammation
Cancer
Solid tumors 1PhI M7824 / TGF beta trap
Therapeutic area: Autoimmune & Inflammation / Cancer
Merck Avelumab Biodrugs/ Drugs Cancer Merkel Cell 1L 2PhII Avelumab
Therapeutic area: Cancer
Merck KGaA Abituzumab Biodrugs/ Drugs Cancer Colorectal Cancer, Prostate cancer, solid tumours 2PhII Abituzumab
Therapeutic area: Cancer
Merck KGaA Atacicept Biodrugs/ Drugs Autoimmune & Inflammation Autoinmune disease 2PhII Atacicept
Therapeutic area: Autoimmune & Inflammation
Merck KGaA Avelumab Biodrugs/ Drugs Cancer Several types of cancer 3PhIII Avelumab
Therapeutic area: Cancer
Merck KGaA Evofosfamida Biodrugs/ Drugs Cancer
Dermatology
Digestive System
Pancreas, cancer, sarcoma 4Reg. Evofosfamida
Therapeutic area: Cancer / Dermatology / Digestive System
Merck KGaA Pimasertib Biodrugs/ Drugs Cancer Colorectal Cancer, Pancreas, Melanoma, solid tumours and ovarian cancer 4Reg. Pimasertib
Therapeutic area: Cancer
MSD mk7655A Biodrugs/ Drugs Infections Subjects with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia 3PhIII mk7655A
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Study of Chemotherapy with or without Pembrolizumab in TKI-resistant EGFR-mutated Tumors in Metastatic Non-Squamous Non-small Cell Lung Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD LAG3 Biodrugs/ Drugs Cancer 6 Select Advanced Solid Tumors 1PhI LAG3
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Advanced Renal Cell Carcinoma (RCC) 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Advanced Gastric or Gastroesophageal Junction Adenocarcinoma First line 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in subjects with relapsed or refractory classical Hodgkin Lymphoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Metastatic Triple-Negative Breast Cancer (mTNBC) 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in subjects with relapsed of refractory classical hodgkin lymphona 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD ZERBAXA Biodrugs/ Drugs Infections Pediatric Subjects with Complicated Intra-Abdominal Infection 2PhII ZERBAXA
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Neoadjuvant registration study -Triple negative breast cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in combination with Daratumumab in subjects Multiple Myeloma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD BET Inhibitor Biodrugs/ Drugs Cancer 4 Select Advanced Solid Tumors 1PhI BET Inhibitor
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Advanced Gastric or Gastroesophageal Junction Adenocarcinoma after First Line Progression 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Anacetrapib Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Coronary Heart Disease (CHD) or CHD Risk- Equivalent Disease 3PhIII Anacetrapib
Therapeutic area: Cardiovascular and circulatory systems / Metabolic / Endocrinology
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in recurrent or metastatic cutaneous squamous cell carcinoma 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Doravirine Biodrugs/ Drugs Infections HIV Infection 3PhIII Doravirine
Therapeutic area: Infections
MSD ZINPLAVA Biodrugs/ Drugs Infections in Children Aged 1 to <18 Years Receiving Antibacterial Drug Treatment for C. difficile Infection (Toxin B) 3PhIII ZINPLAVA
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer 1st Line mTNBC choice of Taxane +/- Pembro-Triple negative breast cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab Plus Rituximab Versus Rituximab in Subjects With Relapsed Follicular Lymphoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD V114 Biodrugs/ Drugs Infections Prevention of Pneumococal infection with V114 2PhII V114
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer MSI-H or dMMR Stage IV Colorectal Carcinoma after progression of first and second line standart therapy 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Advanced/Unresectable or Metastatic Urothelial Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD MK7254 Biodrugs/ Drugs Respiratory and Pulmonary system Chronic cough 2PhII MK7254
Therapeutic area: Respiratory and Pulmonary system
MSD Elbasvir/Grazoprevir Biodrugs/ Drugs Infections Chronic Hepatitis C 3PhIII Elbasvir/Grazoprevir
Therapeutic area: Infections
MSD Prevymis (Letermovir) Biodrugs/ Drugs Infections Prevention of CMV disease in D+/R- kidney transplant recipients 3PhIII Prevymis (Letermovir)
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer ER+Neoadjuvant -Breast-Oestrogen receptor positive breast cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembroluzimab given concomitantly with chemoradiation in subjects with locally advanced head and neck squamous cell carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD SItagliptin Biodrugs/ Drugs Metabolic / Endocrinology Type 2 Diabetes and milf renal imparment 3PhIII SItagliptin
Therapeutic area: Metabolic / Endocrinology
MSD Pembrolizumab Biodrugs/ Drugs Cancer Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have progressed after First Line Standard Therapy 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD V114 Vaccines Infections Pneumoccoco in healthy adults 50 years of age or older 3PhIII V114
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in subjects with recurrent ovarian cancer 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Odanacatib Biodrugs/ Drugs Musculoskeletal Disorders
Women´s health
Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium 3PhIII Odanacatib
Therapeutic area: Musculoskeletal Disorders / Women´s health
MSD Etonogestrel+ Estradiol (vaginal ring) Biodrugs/ Drugs Women´s health Contraception 3PhIII Etonogestrel+ Estradiol (vaginal ring)
Therapeutic area: Women´s health
MSD Pembrolizumab Biodrugs/ Drugs Cancer Progressive or recurrent Intermediate or High risk, Non-muscle invasive Urothelial Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil in Subjects with Advanced/Metastatic Esophageal Carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Posaconazole Biodrugs/ Drugs Infections Posaconazole for the treatment of invasive aspergillosis in adults and adolescents. 3PhIII Posaconazole
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer 20 Select Advanced Solid Tumors 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Golimumab Biodrugs/ Drugs Autoimmune & Inflammation Non-radiographic axial Spondyloarthritis 4Reg. Golimumab
Therapeutic area: Autoimmune & Inflammation
MSD V160 Vaccines Infections Prevention CMVin women 16-35 dosis vx 3 dosis 2PhII V160
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer MSI-H or dMMR Stage IV Colorectal Carcinoma (after progression of First and second line Standard Therapy) 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Raltegravir Biodrugs/ Drugs Infections HIV Infection 3PhIII Raltegravir
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Gardasil 9 Biodrugs/ Drugs Infections Prevention of HPV infection with Gardasil 9 in adult women 27-45 3PhIII Gardasil 9
Therapeutic area: Infections
MSD ZERBAXA Biodrugs/ Drugs Infections Adult Patients with Ventilated Nosocomial Pneumonia 3PhIII ZERBAXA
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pemetrexed+Platinum with or without Pembrolizumab in first line (1L) metastatic non-squamous NSCLC 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer 10 Select Advanced Solid Tumors 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Posaconazole Biodrugs/ Drugs Infections Prophylaxis of invasive fungal infections in immunocompromised pediatric subjects with neutropenia or expected neutropenia 1PhI Posaconazole
Therapeutic area: Infections
MSD Sitagliptin Biodrugs/ Drugs Metabolic / Endocrinology Type 2 Diabetes 3PhIII Sitagliptin
Therapeutic area: Metabolic / Endocrinology
MSD Mk1645 Vaccines Infections prevention VRS in pre term and full term infants 2PhII Mk1645
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Fosaprepitant Biodrugs/ Drugs Cancer Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy 3PhIII Fosaprepitant
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Trastuzumab + Chemotherapywith or without Pembrolizumab as First-line Treatment in Participants With HER2 Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Elbasvir/Grazoprevir Biodrugs/ Drugs Infections Chronic Hepatitis C 3PhIII Elbasvir/Grazoprevir
Therapeutic area: Infections
MSD ZERBAXA Biodrugs/ Drugs Assess the Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) Ceftolozane/Tazobactam in Critically Ill Patients 1PhI ZERBAXA
Therapeutic area:
MSD Pembrolizumab Biodrugs/ Drugs Cancer first Line Study of Pembrolizumab +/- Ipilimumab in NSCLC 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Patients with a histologically confirmed diagnosis of melanoma (MEL) with unresectable or metastatic disease that have not received ipilimumab (IPI) treatment 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Prevymis (Letermovir) Biodrugs/ Drugs Infections Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients 3PhIII Prevymis (Letermovir)
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer First line study of pembrolizumab +/- epacadostat in NSCLC 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with Advanced Endometrial Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer First line etoposide/platinum with or without pembrolizumab in extensive stage small cell lung cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD V920 Vaccines Infections Three consistency lot doses and high dose of rVSV-ZEBOV-GiP (V920 ebola vaccine) in Healthy Adults 3PhIII V920
Therapeutic area: Infections
MSD SIVEXTRO Biodrugs/ Drugs Infections Ventilated Gram-positive Nosocomial Pneumonia 3PhIII SIVEXTRO
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Subjects with histologically confirmed diagnosis of melanoma with unresectable or metastatic melanoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Inactivated VZV Vaccine Vaccines Blood and Lymphatic systems
Cancer
Adult Patients with Solid Tumor or Hematologic Malignancy 3PhIII Inactivated VZV Vaccine
Therapeutic area: Blood and Lymphatic systems / Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer In combination with Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab vs chemotherapy in patients with advanced melanoma 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Study of Pembrolizumab/Epacadostat/Chemotherapy in Metastatic Non-small Cell Lung Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Gardasil Biodrugs/ Drugs Infections Prevention of HPV infection with Gardasil in Young Men 3PhIII Gardasil
Therapeutic area: Infections
MSD SIVEXTRO Biodrugs/ Drugs Infections Subjects 12 to <18 Years with complicated Skin and Soft Tissue Infections (cSSTI) 3PhIII SIVEXTRO
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Lenalidomide and low dose dexamethasone with Pembrolizumab in Newly diagnosed and treated naive Multiple Myeloma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Recurrent or Progressive Metastatic Urothelial Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in combination with lenalidomide and dexamethasone in subjects Multiple Myeloma 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembro Combination Dose Escalation/MTD (IT)-Solid tumour-Rigontec GmbH-INTRATUMOR 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer "Chemo +/- Pembrolizumab as Perioperative Therapy for Resectable Stage IIB or IIIA Non-small Cell Lung Cancer" 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Gardasil 9 Vaccines Infections VPH in preadolescents and adolescents 3PhIII Gardasil 9
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Previously Treated Subjects with Squamous Histology Non-Small Cell Lung Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pomalidomide and low dose dexamethasone with pembrolizumab in refractory or relapsed Multiple Myeloma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer First line treatment of recurrent/Metastasic Head and Neck Squamous Cell Carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab plus Epacadostat vs SOC (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Adjuvant Therapy with Pembrolizumab Vs. Placebo in Resected Stage II Melanoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in combination with axitinib versus sunitinib monotherapy as a first-line treatment for advanced or metastatic clear-cell renal cell carcinoma. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Vericiguat Biodrugs/ Drugs Cardiovascular and circulatory systems Heart failure with reduced ejection Fraction 3PhIII Vericiguat
Therapeutic area: Cardiovascular and circulatory systems
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab versus standard Treatment in subjects with recurrent or metastatic Head and Neck Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer PD-L1 Strong Metastatic Non-Small Cell Lung Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Verubecestat Biodrugs/ Drugs Central Nervous System Alzheimer's Disease 3PhIII Verubecestat
Therapeutic area: Central Nervous System
Novo Nordisk Pharma Semaglutide NASH Biodrugs/ Drugs Metabolic / Endocrinology Non-alcoholic steatohepatitis 2PhII Semaglutide NASH
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Prandial Bioedge Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 and 2 1PhI Prandial Bioedge
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Semaglutide obesidad Biodrugs/ Drugs Metabolic / Endocrinology Obesity 3PhIII Semaglutide obesidad
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma AM833 (amilyn analogue) Biodrugs/ Drugs Metabolic / Endocrinology Obesity 1PhI AM833 (amilyn analogue)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Somapacitan(Long-acting growth hormone) Biodrugs/ Drugs Metabolic / Endocrinology Growth hormone deficiency 3PhIII Somapacitan(Long-acting growth hormone)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma G530L (glucagon analogue/liraglutide) Biodrugs/ Drugs Metabolic / Endocrinology Obesity 1PhI G530L (glucagon analogue/liraglutide)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Concizumab Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia A and B 2PhII Concizumab
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma Monoclonal antibody anti Il-21 Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 2PhII Monoclonal antibody anti Il-21
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma PYY1562 (analogue peptid YY) Biodrugs/ Drugs Metabolic / Endocrinology Obesity 1PhI PYY1562 (analogue peptid YY)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Semaglutide Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 3PhIII Semaglutide
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Oral semaglutide Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 3PhIII Oral semaglutide
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma IDegAsp (combination insulin degludec + insulin aspart) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 and type 1 4Reg. IDegAsp (combination insulin degludec + insulin aspart)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Liraglutide Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 in paediatric population 3PhIII Liraglutide
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma IDegLira (combination insulin degludec + liraglutide) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 4Reg. IDegLira (combination insulin degludec + liraglutide)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Nonacog beta pegol Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia B 4Reg. Nonacog beta pegol
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma Liraglutide 3mg Biodrugs/ Drugs Metabolic / Endocrinology Obesity 4Reg. Liraglutide 3mg
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma N8-GP (glycopegylated recombinant FVIII) Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia A 3PhIII N8-GP (glycopegylated recombinant FVIII)
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma Turoctocog alfa Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia A 4Reg. Turoctocog alfa
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma Insulin LA287 Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 and 2 1PhI Insulin LA287
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Faster-acting insulin aspart (FIAsp) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 and type 2 4Reg. Faster-acting insulin aspart (FIAsp)
Therapeutic area: Metabolic / Endocrinology
Roche OX40 Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI OX40
Therapeutic area: Cancer
Roche ERIVEDGE Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII ERIVEDGE
Therapeutic area: Cancer
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche PARSATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII PARSATUZUMAB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer other unspecificed types of non-hodgkin's lymphoma 2PhII Tecentriq
Therapeutic area: Cancer
Roche MABTHERA Biodrugs/ Drugs Cardiovascular and circulatory systems Other necrotizing vasculopathies 3PhIII MABTHERA
Therapeutic area: Cardiovascular and circulatory systems
Roche ZELBORAF Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII ZELBORAF
Therapeutic area: Cancer
Roche FENEBRUTINIB Biodrugs/ Drugs Autoimmune & Inflammation systemic lupus erythematosus 2PhII FENEBRUTINIB
Therapeutic area: Autoimmune & Inflammation
Roche CRENEZUMAB Biodrugs/ Drugs Central Nervous System Alzheimer's disease 3PhIII CRENEZUMAB
Therapeutic area: Central Nervous System
Roche PERJETA Biodrugs/ Drugs Cancer Malignant neoplasm of ovary 3PhIII PERJETA
Therapeutic area: Cancer
Roche ALECENSA Biodrugs/ Drugs Cancer Non-small cell lung cancer 4Reg. ALECENSA
Therapeutic area: Cancer
Roche FAP IL2V FP Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI FAP IL2V FP
Therapeutic area: Cancer
Roche CD20 CD3 TDB Biodrugs/ Drugs Blood and Lymphatic systems Diffuse non-hodgkin's lymphoma 1PhI CD20 CD3 TDB
Therapeutic area: Blood and Lymphatic systems
Roche Myostatin Biodrugs/ Drugs Musculoskeletal Disorders Duchenne muscular dystrophy 3PhIII Myostatin
Therapeutic area: Musculoskeletal Disorders
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI PDL1 MAB
Therapeutic area: Cancer
Roche ALECTINIB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 3PhIII ALECTINIB
Therapeutic area: Cancer
Roche COBIMETINIB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI COBIMETINIB
Therapeutic area: Cancer
Roche Venclexta Biodrugs/ Drugs Blood and Lymphatic systems Diffuse non-hodgkin's Lymphoma 2PhII Venclexta
Therapeutic area: Blood and Lymphatic systems
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 2PhII IMGATUZUMAB
Therapeutic area: Cancer
Roche Tau Mab (37D3) Biodrugs/ Drugs Central Nervous System Alzheimer's disease 2PhII Tau Mab (37D3)
Therapeutic area: Central Nervous System
Roche ACTEMRA Biodrugs/ Drugs Autoimmune & Inflammation Other disorders involving the immune mechanism 3PhIII ACTEMRA
Therapeutic area: Autoimmune & Inflammation
Roche PLGF MAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI PLGF MAB
Therapeutic area: Cancer
Roche ERIVEDGE Biodrugs/ Drugs Autoimmune & Inflammation
Cancer
Other disorders involving the immune mechanism 2PhII ERIVEDGE
Therapeutic area: Autoimmune & Inflammation / Cancer
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Malignant neoplasms of lymphoid haematopoietic + 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of kidney except renal pelvis 2PhII PDL1 MAB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer Ovarian cancer 3PhIII Tecentriq
Therapeutic area: Cancer
Roche MABTHERA Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Pemphigus 3PhIII MABTHERA
Therapeutic area: Autoimmune & Inflammation / Dermatology
Roche ACTEMRA Biodrugs/ Drugs Cardiovascular and circulatory systems Giant Cel arteritis 3PhIII ACTEMRA
Therapeutic area: Cardiovascular and circulatory systems
Roche Idasanutlin Biodrugs/ Drugs Blood and Lymphatic systems Leukaemia Acute 3PhIII Idasanutlin
Therapeutic area: Blood and Lymphatic systems
Roche DANOPREVIR Biodrugs/ Drugs Infections Chronic viral haepatitis 2PhII DANOPREVIR
Therapeutic area: Infections
Roche Balovaptan Biodrugs/ Drugs Central Nervous System Autism 3PhIII Balovaptan
Therapeutic area: Central Nervous System
Roche FAP IL2V FP Biodrugs/ Drugs Cancer non-Small cell lung cancer 2PhII FAP IL2V FP
Therapeutic area: Cancer
Roche OCREVUS Biodrugs/ Drugs Central Nervous System Multiple Sclerosis 4Reg. OCREVUS
Therapeutic area: Central Nervous System
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI PDL1 MAB
Therapeutic area: Cancer
Roche BITOPERTIN Biodrugs/ Drugs Central Nervous System Schizophrenia 3PhIII BITOPERTIN
Therapeutic area: Central Nervous System
Roche DULIGOTUZUMAB Biodrugs/ Drugs Cancer Other malignant neoplasms of skin 1PhI DULIGOTUZUMAB
Therapeutic area: Cancer
Roche Venclexta Biodrugs/ Drugs Blood and Lymphatic systems Lymphoid leukaemia 3PhIII Venclexta
Therapeutic area: Blood and Lymphatic systems
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII IMGATUZUMAB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer breast cancer 3PhIII Tecentriq
Therapeutic area: Cancer
Roche ACTEMRA Biodrugs/ Drugs Cardiovascular and circulatory systems Peripheral Vascular Diseases 3PhIII ACTEMRA
Therapeutic area: Cardiovascular and circulatory systems
Roche ACTEMRA Biodrugs/ Drugs Autoimmune & Inflammation Rheumatoid arthristis ( juvenile) 4Reg. ACTEMRA
Therapeutic area: Autoimmune & Inflammation
Roche FORTOVASE Biodrugs/ Drugs Infections HIV disease unspecified 2PhII FORTOVASE
Therapeutic area: Infections
Roche KADCYLA Biodrugs/ Drugs Cancer Malignant neoplasm of breast 3PhIII KADCYLA
Therapeutic area: Cancer
Roche PICTILISIB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 2PhII PICTILISIB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer plasma cell neoplasm 3PhIII Tecentriq
Therapeutic area: Cancer
Roche MABTHERA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse non-Hodgkin's lymphoma, unspecified 3PhIII MABTHERA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche CD20 CD3 TDB Biodrugs/ Drugs Blood and Lymphatic systems Malignant neoplams of lymphoid haematopoietic 1PhI CD20 CD3 TDB
Therapeutic area: Blood and Lymphatic systems
Roche IPATASERTIB Biodrugs/ Drugs Cancer Breast cancer 2PhII IPATASERTIB
Therapeutic area: Cancer
Roche DULIGOTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII DULIGOTUZUMAB
Therapeutic area: Cancer
Roche BET Biodrugs/ Drugs Blood and Lymphatic systems Diffuse non-hodgkin's lymphoma 1PhI BET
Therapeutic area: Blood and Lymphatic systems
Roche GAZYVA Biodrugs/ Drugs Autoimmune & Inflammation systemic lupus erythematosus 2PhII GAZYVA
Therapeutic area: Autoimmune & Inflammation
Roche ACTEMRA Biodrugs/ Drugs Metabolic / Endocrinology Thyrotoxicosis (hyperthyroidism) 3PhIII ACTEMRA
Therapeutic area: Metabolic / Endocrinology
Roche OCREVUS Biodrugs/ Drugs Central Nervous System Primary progresive multiple sclerosis 3PhIII OCREVUS
Therapeutic area: Central Nervous System
Roche TASELISIB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI TASELISIB
Therapeutic area: Cancer
Roche OCRELIZUMAB Biodrugs/ Drugs Central Nervous System Musculoskeletal Disorders 3PhIII OCRELIZUMAB
Therapeutic area: Central Nervous System
Roche ZELBORAF Biodrugs/ Drugs Cancer Malignant melanoma of skin 4Reg. ZELBORAF
Therapeutic area: Cancer
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 2PhII IPATASERTIB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer Head and neck cancer 3PhIII Tecentriq
Therapeutic area: Cancer
Roche ACTEMRA Biodrugs/ Drugs Autoimmune & Inflammation systemic sclerosis 3PhIII ACTEMRA
Therapeutic area: Autoimmune & Inflammation
Roche HERCEPTIN Biodrugs/ Drugs Cancer Malignant neoplasm of bladder 2PhII HERCEPTIN
Therapeutic area: Cancer
Roche KADCYLA Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII KADCYLA
Therapeutic area: Cancer
Roche PICTILISIB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 2PhII PICTILISIB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer Prostate cancer 3PhIII Tecentriq
Therapeutic area: Cancer
Roche MABTHERA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 3PhIII MABTHERA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche CD20 CD3 TDB Biodrugs/ Drugs Blood and Lymphatic systems Non-hodgkin's lymphoma 1PhI CD20 CD3 TDB
Therapeutic area: Blood and Lymphatic systems
Roche IPATASERTIB Biodrugs/ Drugs Cancer Prostate cancer 3PhIII IPATASERTIB
Therapeutic area: Cancer
Roche DULIGOTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasms 2PhII DULIGOTUZUMAB
Therapeutic area: Cancer
Roche COTELLIC Biodrugs/ Drugs Cancer Breast cancer 2PhII COTELLIC
Therapeutic area: Cancer
Roche HEMLIBRA Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia A 3PhIII HEMLIBRA
Therapeutic area: Blood and Lymphatic systems
Roche EM RA PRED DEV Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn's disease 1PhI EM RA PRED DEV
Therapeutic area: Autoimmune & Inflammation / Digestive System
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasm of prostate 2PhII IPATASERTIB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer Hepatocellular carcinoma 3PhIII Tecentriq
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of brain 3PhIII AVASTIN
Therapeutic area: Cancer
Roche OCREVUS Biodrugs/ Drugs Central Nervous System Relapsing-remitting multiple sclerosis 3PhIII OCREVUS
Therapeutic area: Central Nervous System
Roche VANUCIZUMAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI VANUCIZUMAB
Therapeutic area: Cancer
Roche ALEGLITAZAR Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Atherosclerosis 3PhIII ALEGLITAZAR
Therapeutic area: Cardiovascular and circulatory systems / Metabolic / Endocrinology
Roche LIFASTUZUMAB VEDOTIN Biodrugs/ Drugs Cancer Malignant neoplasm of ovary 2PhII LIFASTUZUMAB VEDOTIN
Therapeutic area: Cancer
Roche OCRELIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Rheumatoid arthritis 3PhIII OCRELIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche SEMBRAGILINE Biodrugs/ Drugs Central Nervous System Alzheimer's disease 2PhII SEMBRAGILINE
Therapeutic area: Central Nervous System
Roche Tecentriq Biodrugs/ Drugs Cancer Renal cell carcinoma 3PhIII Tecentriq
Therapeutic area: Cancer
Roche MABTHERA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Other + unspecif. types of non-Hodgkin's lymphoma 3PhIII MABTHERA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche CEA CD3 TCB Biodrugs/ Drugs Cancer colorectal cancer 1PhI CEA CD3 TCB
Therapeutic area: Cancer
Roche ETROLIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn's disease 3PhIII ETROLIZUMAB
Therapeutic area: Autoimmune & Inflammation / Digestive System
Roche IPATASERTIB Biodrugs/ Drugs Cancer triple negative breast cancer 3PhIII IPATASERTIB
Therapeutic area: Cancer
Roche EM ACTEMAB RA Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Rheumatoid arthritis 2PhII EM ACTEMAB RA
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche COTELLIC Biodrugs/ Drugs Cancer Colorectal cancer 3PhIII COTELLIC
Therapeutic area: Cancer
Roche herceptin Biodrugs/ Drugs Cancer Breast cancer 3PhIII herceptin
Therapeutic area: Cancer
Roche ALEGLITAZAR Biodrugs/ Drugs Metabolic / Endocrinology Diabetes Mellitus 3PhIII ALEGLITAZAR
Therapeutic area: Metabolic / Endocrinology
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 2PhII IPATASERTIB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer kidney cancer 3PhIII Tecentriq
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of ovary 3PhIII AVASTIN
Therapeutic area: Cancer
Roche OCREVUS Biodrugs/ Drugs Cancer Renal cancer carncinoma 3PhIII OCREVUS
Therapeutic area: Cancer
Roche VENETOCLAX Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse non-Hodgkin's lymphoma, unspecified 1PhI VENETOCLAX
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche Asyn MAb Biodrugs/ Drugs Central Nervous System Parkinson's disease 2PhII Asyn MAb
Therapeutic area: Central Nervous System
Roche NEORECORMON Biodrugs/ Drugs Blood and Lymphatic systems Anaemia in neoplastic disease 2PhII NEORECORMON
Therapeutic area: Blood and Lymphatic systems
Roche OCRELIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Systemic lupus erythematosus 3PhIII OCRELIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche VANUCIZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII VANUCIZUMAB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer triple negative breast cancer 3PhIII Tecentriq
Therapeutic area: Cancer
Roche PEGASYS Biodrugs/ Drugs Infections Chronic viral haepatitis 3PhIII PEGASYS
Therapeutic area: Infections
Roche CEA CD3 TCB Biodrugs/ Drugs Cancer Pancreatic cancer 1PhI CEA CD3 TCB
Therapeutic area: Cancer
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 1PhI IMGATUZUMAB
Therapeutic area: Cancer
Roche MIRCERA Biodrugs/ Drugs Blood and Lymphatic systems Chronic renal failure anemia 2PhII MIRCERA
Therapeutic area: Blood and Lymphatic systems
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 2PhII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche herceptin Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 4Reg. herceptin
Therapeutic area: Cancer
Roche COBIMETINIB Biodrugs/ Drugs Cancer Malignant melanoma of skin 3PhIII COBIMETINIB
Therapeutic area: Cancer
Roche KADCYLA Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 2PhII KADCYLA
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer Malignant neoplasm of bladder 3PhIII Tecentriq
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII AVASTIN
Therapeutic area: Cancer
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 3PhIII ONARTUZUMAB
Therapeutic area: Cancer
Roche CD40 IMAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CD40 IMAB
Therapeutic area: Cancer
Roche CEACAM5 CEA TCB Biodrugs/ Drugs Cancer Solid tumor 1PhI CEACAM5 CEA TCB
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer breast cancer 4Reg. AVASTIN
Therapeutic area: Cancer
Roche PATECLIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Rheumatoid arthritis 2PhII PATECLIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche COTELLIC Biodrugs/ Drugs Cancer Malignant melanoma of skin 4Reg. COTELLIC
Therapeutic area: Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 3PhIII PDL1 MAB
Therapeutic area: Cancer
Roche TIRAGOLUMAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI TIRAGOLUMAB
Therapeutic area: Cancer
Roche TAMIFLU Biodrugs/ Drugs Infections Influenza 1PhI TAMIFLU
Therapeutic area: Infections
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI IMGATUZUMAB
Therapeutic area: Cancer
Roche APITOLISIB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI APITOLISIB
Therapeutic area: Cancer
Roche mPI3K alpha inh Biodrugs/ Drugs Cancer Breast cancer 1PhI mPI3K alpha inh
Therapeutic area: Cancer
Roche GAZYVA Biodrugs/ Drugs Cancer Malignant neoplasm of other and unspecified parts of biliary tract 3PhIII GAZYVA
Therapeutic area: Cancer
Roche IL22 Fc Biodrugs/ Drugs Autoimmune & Inflammation Other disorders involving the immune mechanism 1PhI IL22 Fc
Therapeutic area: Autoimmune & Inflammation
Roche ETROLIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Irritable bowel syndrome 3PhIII ETROLIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche LEBRIKIZUMAB Biodrugs/ Drugs Respiratory and Pulmonary system Other diseases of upper respiratory tract 2PhII LEBRIKIZUMAB
Therapeutic area: Respiratory and Pulmonary system
Roche Tecentriq Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 4Reg. Tecentriq
Therapeutic area: Cancer
Roche DALCETRAPIB Biodrugs/ Drugs Cardiovascular and circulatory systems Acute myocardial infarction 3PhIII DALCETRAPIB
Therapeutic area: Cardiovascular and circulatory systems
Roche OX40 Biodrugs/ Drugs Cancer Breast cancer 4Reg. OX40
Therapeutic area: Cancer
Roche CEA CD3 TCB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CEA CD3 TCB
Therapeutic area: Cancer
Roche ALPHA7 NIC AGO Biodrugs/ Drugs Central Nervous System Alzheimer's disease 2PhII ALPHA7 NIC AGO
Therapeutic area: Central Nervous System
Roche TIRAGOLUMAB Biodrugs/ Drugs Cancer Solid tumor 2PhII TIRAGOLUMAB
Therapeutic area: Cancer
Roche TASPOGLUTIDE Biodrugs/ Drugs Metabolic / Endocrinology Diabetes Mellitus 3PhIII TASPOGLUTIDE
Therapeutic area: Metabolic / Endocrinology
Roche Cergutuzumab amunaleukin Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI Cergutuzumab amunaleukin
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Cervical cancer 2PhII AVASTIN
Therapeutic area: Cancer
Roche POLATUZUMAB VEDOTIN Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Follicular (nodular) non-Hodgkin's lymphoma 2PhII POLATUZUMAB VEDOTIN
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche COTELLIC Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII COTELLIC
Therapeutic area: Cancer
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 3PhIII ONARTUZUMAB
Therapeutic area: Cancer
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI IPATASERTIB
Therapeutic area: Cancer
Roche APITOLISIB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI APITOLISIB
Therapeutic area: Cancer
Roche SERD (2) Biodrugs/ Drugs Cancer Breast cancer 1PhI SERD (2)
Therapeutic area: Cancer
Roche GPC3 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of liver 2PhII GPC3 MAB
Therapeutic area: Cancer
Roche PERJETA Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII PERJETA
Therapeutic area: Cancer
Roche APITOLISIB Biodrugs/ Drugs Cancer Malignant neoplasm of kidney except renal pelvis 2PhII APITOLISIB
Therapeutic area: Cancer
Roche IL22 Fc Biodrugs/ Drugs Autoimmune & Inflammation Ulcerative colitis 2PhII IL22 Fc
Therapeutic area: Autoimmune & Inflammation
Roche ANTI-INFLUENZA A Biodrugs/ Drugs Infections Influenza 2PhII ANTI-INFLUENZA A
Therapeutic area: Infections
Roche GANTENERUMAB Biodrugs/ Drugs Central Nervous System Alzheimer's disease 3PhIII GANTENERUMAB
Therapeutic area: Central Nervous System
Roche MERICITABINE Biodrugs/ Drugs Infections Chronic viral haepatitis 2PhII MERICITABINE
Therapeutic area: Infections
Roche Tecentriq Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII Tecentriq
Therapeutic area: Cancer
Roche DALCETRAPIB Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Atherosclerosis 3PhIII DALCETRAPIB
Therapeutic area: Cardiovascular and circulatory systems / Metabolic / Endocrinology
Roche POLATUZUMAB VEDOTIN Biodrugs/ Drugs Blood and Lymphatic systems Diffuse non-hodgkin's lymphoma 3PhIII POLATUZUMAB VEDOTIN
Therapeutic area: Blood and Lymphatic systems
Roche CIF MEK INH Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CIF MEK INH
Therapeutic area: Cancer
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII ONARTUZUMAB
Therapeutic area: Cancer
Roche VEFG- ANG2 Bsb Biodrugs/ Drugs Ophthalmology and optometry Retinal disorders other 3PhIII VEFG- ANG2 Bsb
Therapeutic area: Ophthalmology and optometry
Roche VALCYTE Biodrugs/ Drugs Autoimmune & Inflammation Transplanted organ and tissue status (Excl. complications) 3PhIII VALCYTE
Therapeutic area: Autoimmune & Inflammation
Roche DSTA4637S Biodrugs/ Drugs Infections Bacterial infection of unespecified site 1PhI DSTA4637S
Therapeutic area: Infections
Roche AVASTIN Biodrugs/ Drugs Cancer Colorectal cancer 2PhII AVASTIN
Therapeutic area: Cancer
Roche TARCEVA Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 2PhII TARCEVA
Therapeutic area: Cancer
Roche COTELLIC Biodrugs/ Drugs Cancer Metastases 2PhII COTELLIC
Therapeutic area: Cancer
Roche LUMRETUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 1PhI LUMRETUZUMAB
Therapeutic area: Cancer
Roche BRAF KIN INH (2) Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI BRAF KIN INH (2)
Therapeutic area: Cancer
Roche SERD(3) (9545) Biodrugs/ Drugs Cancer breast cancer metastatic 1PhI SERD(3) (9545)
Therapeutic area: Cancer
Roche HPV16 TI Biodrugs/ Drugs Infections Viral agents as cause of diseases classified to other 2PhII HPV16 TI
Therapeutic area: Infections
Roche TASELISIB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 3PhIII TASELISIB
Therapeutic area: Cancer
Roche BASIMGLURANT Biodrugs/ Drugs Genetic Diseases and Dysmorphic syndromes Fragile X Syndrome 2PhII BASIMGLURANT
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
Roche KADCYLA Biodrugs/ Drugs Cancer Breast cancer 3PhIII KADCYLA
Therapeutic area: Cancer
Roche EM MS BIOMARKER Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn's disease 1PhI EM MS BIOMARKER
Therapeutic area: Autoimmune & Inflammation / Digestive System
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of cervix uteri 2PhII AVASTIN
Therapeutic area: Cancer
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse non-Hodgkin's lymphoma, unspecified 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of brain 2PhII ONARTUZUMAB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer Malignant neoplasms 2PhII Tecentriq
Therapeutic area: Cancer
Roche HCV POL INH PRO Biodrugs/ Drugs Infections Chronic viral haepatitis 3PhIII HCV POL INH PRO
Therapeutic area: Infections
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of bladder 3PhIII PDL1 MAB
Therapeutic area: Cancer
Roche XOLAIR Biodrugs/ Drugs Respiratory and Pulmonary system other diseases of upper respiratory tract 3PhIII XOLAIR
Therapeutic area: Respiratory and Pulmonary system
Roche XELODA Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 3PhIII XELODA
Therapeutic area: Cancer
Roche ETROLIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation ulcerative colitis 3PhIII ETROLIZUMAB
Therapeutic area: Autoimmune & Inflammation
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site. 4Reg. AVASTIN
Therapeutic area: Cancer
Roche TARCEVA Biodrugs/ Drugs Cancer Malignant neoplasm of pancreas 2PhII TARCEVA
Therapeutic area: Cancer
Roche COTELLIC Biodrugs/ Drugs Cancer Plasma cell neoplasm 2PhII COTELLIC
Therapeutic area: Cancer
Roche LUMRETUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 1PhI LUMRETUZUMAB
Therapeutic area: Cancer
Roche CEA IL2V Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CEA IL2V
Therapeutic area: Cancer
Roche TARCEVA Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lungs 4Reg. TARCEVA
Therapeutic area: Cancer
Roche IGF1R MAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII IGF1R MAB
Therapeutic area: Cancer
Roche selicrelumab Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI selicrelumab
Therapeutic area: Cancer
Roche VENETOCLAX Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 3PhIII VENETOCLAX
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche KADCYLA Biodrugs/ Drugs Cancer Malignant neoplasms 2PhII KADCYLA
Therapeutic area: Cancer
Roche LIFASTUZUMAB VEDOTIN Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 1PhI LIFASTUZUMAB VEDOTIN
Therapeutic area: Cancer
Roche ERIVEDGE Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 2PhII ERIVEDGE
Therapeutic area: Cancer
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Follicular (nodular) non-Hodgkin's lymphoma 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 2PhII ONARTUZUMAB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer Non-small cell lung cancer 3PhIII Tecentriq
Therapeutic area: Cancer
Roche LAMPALIZUMAB Biodrugs/ Drugs Ophthalmology and optometry Retinal disorders other 4Reg. LAMPALIZUMAB
Therapeutic area: Ophthalmology and optometry
Roche PERJETA Biodrugs/ Drugs Cancer Malignant neoplasm of breast 3PhIII PERJETA
Therapeutic area: Cancer
Roche ALECENSA Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 3PhIII ALECENSA
Therapeutic area: Cancer
Roche ZELBORAF Biodrugs/ Drugs Cancer Malignant neoplasms 3PhIII ZELBORAF
Therapeutic area: Cancer
Roche FAP 4-1BBL iMAb Biodrugs/ Drugs Cancer Solid tumor 1PhI FAP 4-1BBL iMAb
Therapeutic area: Cancer
Roche cadherin-11 MAb Biodrugs/ Drugs Autoimmune & Inflammation Rheumatoid arthritis 2PhII cadherin-11 MAb
Therapeutic area: Autoimmune & Inflammation
Roche XELODA Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 2PhII XELODA
Therapeutic area: Cancer
Roche Esbriet Biodrugs/ Drugs Respiratory and Pulmonary system Idiophatic pulmonary fibrosis 2PhII Esbriet
Therapeutic area: Respiratory and Pulmonary system
Roche CMV ANTI Biodrugs/ Drugs Infections Cytomegaloviral disease 2PhII CMV ANTI
Therapeutic area: Infections
Roche MabThera Biodrugs/ Drugs Blood and Lymphatic systems Follicular ( nodular) non-hodgkin's lymphoma 3PhIII MabThera
Therapeutic area: Blood and Lymphatic systems
Roche LUMRETUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI LUMRETUZUMAB
Therapeutic area: Cancer
Roche COBIMETINIB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI COBIMETINIB
Therapeutic area: Cancer
Roche TASELISIB Biodrugs/ Drugs Cancer Breast Cancer 3PhIII TASELISIB
Therapeutic area: Cancer
Roche IGF1R MAB Biodrugs/ Drugs Cancer Malignant neoplasms 2PhII IGF1R MAB
Therapeutic area: Cancer
Roche SMN2 splicer (2) Biodrugs/ Drugs Musculoskeletal Disorders Spinal muscular atrophy and related syndromes 3PhIII SMN2 splicer (2)
Therapeutic area: Musculoskeletal Disorders
Roche XOLAIR Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Dermatitis (Allergic Contact) 3PhIII XOLAIR
Therapeutic area: Autoimmune & Inflammation / Dermatology
TiGenix Cx601 Gene / Cell Therapy Autoimmune & Inflammation
Digestive System
Perianal fistula in Crohn disease patients 4Reg. Cx601
Therapeutic area: Autoimmune & Inflammation / Digestive System
TiGenix Cx611 Gene / Cell Therapy Autoimmune & Inflammation
Musculoskeletal Disorders
Rheumatoid arthritis 2PhII Cx611
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
TiGenix Cx611 Gene / Cell Therapy Autoimmune & Inflammation
Infections
Severe sepsis 2PhII Cx611
Therapeutic area: Autoimmune & Inflammation / Infections
TiGenix Cx621 Gene / Cell Therapy Autoimmune & Inflammation No human data available. Development currently on hold. 1PhI Cx621
Therapeutic area: Autoimmune & Inflammation
TiGenix AlloCSC-01 Gene / Cell Therapy Cardiovascular and circulatory systems Acute myocardial infarction 2PhII AlloCSC-01
Therapeutic area: Cardiovascular and circulatory systems